Part D beneficiaries hit hardest under 2019 price hikes

Drug price increases announced beginning Jan. 1 will disproportionately affect Medicare Part D beneficiaries, reinforcing a practice the Trump administration has sought to curb.

Data from Evercore ISI Research on 13 pharmaceutical and biotech companies shows that

Read the full 364 word article

User Sign In